Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 09, 2021

SELL
$73.2 - $107.87 $224,358 - $330,621
-3,065 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$60.45 - $84.26 $185,279 - $258,256
3,065 New
3,065 $236,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.43B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Inscription Capital, LLC Portfolio

Follow Inscription Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Inscription Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inscription Capital, LLC with notifications on news.